Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Alphatec Holdings Inc (ATEC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: ATEC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $18.32
1 Year Target Price $18.32
| 4 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 8.12% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.55B USD | Price to earnings Ratio - | 1Y Target Price 18.32 |
Price to earnings Ratio - | 1Y Target Price 18.32 | ||
Volume (30-day avg) 10 | Beta 1.11 | 52 Weeks Range 4.88 - 13.13 | Updated Date 07/17/2025 |
52 Weeks Range 4.88 - 13.13 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -25.77% | Operating Margin (TTM) -18.74% |
Management Effectiveness
Return on Assets (TTM) -9.33% | Return on Equity (TTM) -291.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2022775189 | Price to Sales(TTM) 2.42 |
Enterprise Value 2022775189 | Price to Sales(TTM) 2.42 | ||
Enterprise Value to Revenue 3.15 | Enterprise Value to EBITDA -18.89 | Shares Outstanding 146172992 | Shares Floating 114153572 |
Shares Outstanding 146172992 | Shares Floating 114153572 | ||
Percent Insiders 21.48 | Percent Institutions 63.36 |
Upturn AI SWOT
Alphatec Holdings Inc
Company Overview
History and Background
Alphatec Holdings, Inc. (ATEC) was founded in 2006. It has grown through acquisitions and internal development to become a significant player in the spinal surgery market.
Core Business Areas
- Spinal Implants: Designs, develops, and markets a range of spinal implants used in surgical procedures to treat spinal disorders.
- Biologics: Offers biologic products used to promote spinal fusion and healing.
- Surgical Access Systems: Provides access systems that facilitate minimally invasive spinal surgery.
- Navigation: Offers a navigation and imaging system to improve surgical accuracy.
Leadership and Structure
ATEC is led by Patrick S. Miles, Chairman and CEO. The company has a typical corporate structure with executive leadership overseeing various departments such as sales, marketing, research and development, and operations.
Top Products and Market Share
Key Offerings
- EOS imaging platform: EOS imaging platform is used for 2D and 3D orthopedic imaging. This generated estimated revenue of $21 million (FY2023). Competitors include Siemens Healthineers, GE Healthcare, and Canon Medical.
- Invictus Spinal Fixation System: Invictus Spinal Fixation System is a posterior fixation system used in spinal surgeries. Market share data is not readily available. Competitors include Medtronic's CD HORIZON, DePuy Synthes' VIPER and NuVasive's RELINE systems.
- SafeOp Neural Monitoring System: The SafeOp Neural Monitoring System helps surgeons avoid nerve damage during procedures. Competitors include Medtronic's NIM-ECLIPSE, and NuVasive's Pulse platform
Market Dynamics
Industry Overview
The spinal device market is characterized by technological innovation, an aging population, and increasing prevalence of spinal disorders. It's a competitive market with both large established players and smaller, innovative companies.
Positioning
ATEC is positioned as a growth-oriented company focused on innovation and expanding its market share in the spinal device market. Their competitive advantage relies on product innovation like the EOS imaging and SafeOp systems as well as their focus on AlphaInformatiX platform.
Total Addressable Market (TAM)
The global spine market is estimated at $10-12 billion. ATEC is targeting a larger share of this market through product innovation and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Strong growth in revenue
- Strategic acquisitions to expand capabilities
- Proprietary technology such as SafeOp
- Focus on data analytics
Weaknesses
- Relatively small market share compared to larger competitors
- History of net losses
- High operating expenses
- Reliance on key personnel
Opportunities
- Increasing adoption of minimally invasive surgery
- Aging population and rising incidence of spinal disorders
- Expansion into new geographic markets
- Development of new technologies and products
- Further acquisitions to expand product lines
Threats
- Intense competition from established players
- Pricing pressures from healthcare providers
- Regulatory hurdles for new products
- Product liability claims
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Stryker (SYK)
- Johnson & Johnson (JNJ)
- Globus Medical (GMED)
- NuVasive (GNTX)
Competitive Landscape
Alphatec is a smaller player competing with larger, more established companies. Its competitive advantage lies in its innovative products, technology and a focused approach.
Major Acquisitions
EOS imaging
- Year: 2020
- Acquisition Price (USD millions): 119.6
- Strategic Rationale: Extended ATEC's portfolio into advanced orthopedic imaging.
Growth Trajectory and Initiatives
Historical Growth: Alphatec has demonstrated strong revenue growth in recent years, driven by product innovation and strategic acquisitions.
Future Projections: Analyst projections estimate continued revenue growth, with a path towards profitability.
Recent Initiatives: Recent initiatives include launching new products, expanding sales force, and acquiring complementary businesses.
Summary
Alphatec is a growth-oriented spinal device company with innovative products and a strategic focus. While they are up against much larger competitors, their strong revenue growth and unique technology, like the SafeOp system, position them well. However, consistent profitability remains a challenge, and they must carefully manage operating expenses and regulatory hurdles to thrive. Expansion into new markets and further innovation will be critical for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Alphatec Holdings Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Analyst Estimates
- Company press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and estimates are subject to change. Investors should conduct their own research before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alphatec Holdings Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2006-06-02 | Executive Chairman, CEO & President Mr. Patrick S. Miles | ||
Sector Healthcare | Industry Medical Devices | Full time employees 867 | Website https://www.atecspine.com |
Full time employees 867 | Website https://www.atecspine.com | ||
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants and instruments. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.